New combo therapy targets tough lymphoma in early trial
NCT ID NCT06139406
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug (JNJ-87801493) combined with immune-activating therapies (T-cell engagers) in about 70 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to other treatments. The main goals are to check safety and find the best dose. The trial is not yet recruiting and is actively ongoing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-87801493 combined with T-cell engagers (JNJ-80948543 or JNJ-75348780)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat B-cell non-Hodgkin lymphoma.
What could go wrong
This is a very early (Phase 1) and small (70 participants) trial focused on safety, not yet on effectiveness. The combination may cause serious side effects like cytokine release syndrome, and it may not work for many patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, 3084, Australia
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Linear Clinical Research Ltd
Nedlands, 6009, Australia
-
Odense University Hospital
Odense, 5000, Denmark
-
Rigshospitalet
Copenhagen, DK-2100, Denmark
-
Scientia Clinical Research
Randwick, 2031, Australia
-
Sourasky (Ichilov) Medical Center
Tel Aviv, 6423906, Israel
-
The Alfred Hospital
Melbourne, 3004, Australia